SCHEMBL6133569

SCHEMBL6133569

CCCNC(=O)c1nc(-c2ccc(F)cc2)c(-c2ccc(=O)n(C(C)C)n2)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 4/20 0.45
PTGS2 P35354 1/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
HSD17B10 Q99714 1/20 0.36
ADORA2A P29274 2/20 0.35
ADORA1 P30542 2/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HIF1A Q16665 1/20 0.35
HDAC1 Q13547 5/20 0.35
HDAC3 O15379 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC4 P56524 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC10 Q969S8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6134311 0.90 HPGD (0.41) MEN1KMT2ANPC1RAB9AHSD17B10
SCHEMBL6133040 0.86 GABRA5 (0.40) HDAC6PTGS2NPC1RAB9AHSD17B10
SCHEMBL6133196 0.85 L3MBTL1 (0.40) HDAC6HSD17B10LMNATP53SMN1; SMN2
SCHEMBL6133208 0.85 NAMPT (0.49) HDAC6MEN1KMT2ANPC1RAB9A
SCHEMBL6134790 0.85 TGFBR1 (0.41) HDAC6PTGS2MEN1KMT2ANPC1
SCHEMBL6133793 0.85 HSD17B10 (0.46) HDAC6MEN1KMT2ARAB9AHSD17B10
SCHEMBL6133269 0.85 HPGD (0.42) HDAC6NPC1RAB9ATP53ALDH1A1
SCHEMBL6133744 0.85 HDAC6 (0.38) HDAC6PTGS2NPC1RAB9AHSD17B10
SCHEMBL6133930 0.84 RET (0.42) HDAC6PTGS2ADORA2AADORA1ALDH1A1
SCHEMBL6133345 0.84 SMN1; SMN2 (0.49) MEN1KMT2ANPC1RAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004134-A1 Thiazole derivative and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004134-A1 Thiazole derivative and pharmaceutical use thereof MC2R, CYP2C9, OXTR HDAC6 222/4885PTGS2 1262/4885MEN1 2508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.